On September 21, 2012, Astex Pharmaceuticals, Inc. issued a press release announcing that clinical development of amuvatinib (MP-470), a multi-targeted tyrosine kinase inhibitor, has been discontinued. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

(d)                 Exhibits



Exhibit
Number                                   Description

99.1 Press release issued by Astex Pharmaceuticals, Inc. on September 21, 2012